The CEO of an oncology company needed to attract 100+ MSEK in venture capital to fund its clinical phase 2 development in a new indication.
MSC was brought in to ghost-write a business plan for the company’s new strategic direction to capture the interest of new investors. Market research was conducted in the new oncology indication to describe treatment algorithms, drug utilization patterns, competitive landscapes and patient epidemiology to support the business case. MSC implemented data from the client’s earlier preclinical and clinical studies, development plans, budget and more to create a plan that was coherent with the company’s past activities. A detailed business plan was delivered to the company Board and the BP was subsequently used to raise the needed capital from a US and European VC consortium.